Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data

@article{deBerardis2013IsTA,
  title={Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data},
  author={Domenico de Berardis and Chiara M. Conti and Stefano Marini and Francesca Ferri and Felice Iasevoli and Alessandro Valchera and Michele Fornaro and Marilde Cavuto and Venkataramanujam Srinivasan and Giampaolo Perna and Alessandro Carano and Monica Piersanti and Giovanni Martinotti and Massimo Di Giannantonio},
  journal={International Journal of Immunopathology and Pharmacology},
  year={2013},
  volume={26},
  pages={299 - 304}
}
Anxiety disorders (ADs) are the most common type of psychiatric disorders. Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic antidepressants (NaSSA) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Agomelatine, a new melatonergic antidepressant, has been shown effective in various types of mood disorders. Moreover, some evidence points… Expand
Agomelatine for the treatment of generalized anxiety disorder
TLDR
Preliminary data would indicate agomelatine as a safe compound, and with a higher rate of clinical response in the short-term and an earlier improvement of symptoms with respect to Selective Serotonine Reuptake Inhibitors (SSRIs) and SelectiveSerotonin Noradrenaline Reuptakes Inhibitor (SNRIs). Expand
Pharmacological Treatment of Panic Disorder with Non-Selective Drugs
TLDR
It is important to use existing scientific evidences regarding effectiveness, tolerability and safety, combined with clinical experience, to plan a rational treatment sequence for panic disorder patients. Expand
Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
TLDR
Current evidences on the role of agomelatine in disorders other than major depression are elucidated to point out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Expand
Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders
TLDR
Fluvoxamine presents high tolerability and safety so that it can be considered as a therapeutic option in case of panic disorder and social anxiety disorder, and its weakness is in extended interaction with CYP450 enzymatic system that may limit its use in elderly or patients with medical comorbidities. Expand
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
TLDR
SSRI/clomipramine in combination with CBT/ERP is associated with the optimal response compared to each treatment alone or to other treatments, and the role of pharmacogenomics could become preponderant in the coming years. Expand
Emerging drugs for the treatment of anxiety
TLDR
This review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Expand
Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report.
TLDR
A case of a patient with major depression and concurrent tamoxifen therapy successfully treated with agomelatine monotherapy is reported, and several antidepressants are potent CYP2D6-inhibiting drugs. Expand
Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations
  • M. Fornaro
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2019
TLDR
Choosing the appropriate pharmacotherapy for OCD/AD comorbidity often proves to be a daunting task for a number of issues, as briefly accounted in the following lines with a set of critical proposals towards effective and safe pharmacotherapy. Expand
Agomelatine: an agent against anhedonia and abulia?
TLDR
Systematic clinical studies are urgently needed to test the hypothesis that agomelatine might be a clinically useful and versatile anti-anhedonic and/or anti-abulic substance. Expand
Vitamin D3 augments the antidepressant effect of agomelatine against repeated corticosterone-induced depressive-like behavior in rats
Background: Depression is a highly complex psychiatric disorder that remains a major burden on society. The present study was aimed to detect the neuroprotective effect of agomelatine or/and vitaminExpand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
TLDR
The role of the melatonergic system in MDD is summarized, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder. Expand
A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
TLDR
Comparison studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well, compared to other antidepressant ones. Expand
Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series
  • M. Fornaro
  • Medicine, Psychology
  • Annals of general psychiatry
  • 2011
TLDR
Agomelatine may have a role in the management of OCD, essentially due to its anxiolytic 5-hydroxytryptamine (HT)2C blockade action, while melatonin (MT)1 and MT2 modulation might contribute to circadian rhythm restoration if impaired. Expand
Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
TLDR
This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated, and additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomalatine in the contemporary pharmacotherapy for anxiety disorders. Expand
A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy.
TLDR
The case of a young female patient with severe OCD who remitted as a result of the initiation of agomelatine monotherapy is described. Expand
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
TLDR
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose. Expand
Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study
TLDR
AGO showed significantly greater efficacy on anhedonia and similar antidepressant efficacy to the serotonin-norepinephrine reuptake inhibitor VLX in patients with major depressive disorder during an 8-week treatment period. Expand
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
TLDR
Agomelatine, a melatonergic antidepressant with a rapid onset of action, has been shown effective in various types of mood disorders and some studies find it superior to other common antidepressants that are in clinical use today. Expand
Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study
TLDR
This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Expand
The melatonergic system: effects on sleep and implications for the treatment of psychiatric disorders
TLDR
The purpose of the present review was to elucidate the effects of the melatonergic system on sleep and the implications for the treatment of psychiatric disorders. Expand
...
1
2
3
4
...